KHK7791
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Dec 27, 2018 → Nov 26, 2019
NCT ID
NCT03831607About KHK7791
KHK7791 is a phase 2 stage product being developed by Kyowa Kirin for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03831607. Target conditions include Hyperphosphatemia.
What happened to similar drugs?
2 of 15 similar drugs in Hyperphosphatemia were approved
Approved (2) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04771780 | Phase 3 | Completed |
| NCT04766385 | Phase 3 | Completed |
| NCT03831607 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperphosphatemia